Whitehawk Therapeutics, Inc. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
In May 2026, Whitehawk closed an $87.5M private placement equity financing from existing and new investors including Avoro Capital, QVT, Coastlands Capital, and others, raising cash to $190.0M as of June 30, 2026 (vs. $145.7M at year-end 2025). The company expects cash to fund operations into 2H 2028. Q2 2026 net loss was $16.6M (vs. $52.6M in Q2 2025, which included a $38.0M WuXi Biologics license fee); R&D spend was $12.9M. Operationally, HWK-007 and HWK-016 Phase 1 trials continue enrolling; HWK-206 Phase 1 planned to initiate Q3 2026. Company also signed option agreement with Hangzhou DAC for CPT113 linker-payload access (up to 5 new ADC programs) and collaboration with Biocytogen for bispecific antibody ADCs.
Why this rating
$87.5M raise is ~135% of market cap—substantial capital infusion extending runway 18+ months. Clinical progress on three assets is on track. Partnerships expand platform optionality. However, company remains pre-revenue, unprofitable, and execution risk remains high.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.